期刊
NATURE REVIEWS GENETICS
卷 19, 期 4, 页码 235-+出版社
NATURE PORTFOLIO
DOI: 10.1038/nrg.2017.108
关键词
-
资金
- National Institute for Health Research
- Medical Research Council (MRC)
- Engineering and Physical Sciences Research Council (EPSRC)
- Lupus UK
- Swedish Foundation for Humanities and Social Sciences
- Wellcome Trust
- MRC
- EPSRC
- MRC [MR/M01665X/1]
- Medical Research Council [MR/N00583X/1] Funding Source: researchfish
- Wellcome Trust [203405/Z/16/Z] Funding Source: researchfish
- MRC [MR/N00583X/1] Funding Source: UKRI
- Wellcome Trust [203405/Z/16/Z] Funding Source: Wellcome Trust
Developments in next-generation sequencing technologies have driven the clinical application of diagnostic tests that interrogate the whole genome, which offer the chance to diagnose rare inherited diseases or inform the targeting of therapies. New genomic diagnostic tests compete with traditional approaches to diagnosis, including the genetic testing of single genes and other clinical strategies, for finite health-care budgets. In this context, decision analytic model-based cost-effectiveness analysis is a useful method to help evaluate the costs versus consequences of introducing new health-care interventions. This Perspective presents key methodological, technical, practical and organizational challenges that must be considered by decision-makers responsible for the allocation of health-care resources to obtain robust and timely information about the relative cost-effectiveness of the increasing numbers of emerging genomic tests.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据